- Home
- USCB vs ESPR Comparison
USCB vs ESPR Comparison
Compare USCB & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- ESPR
- Stock Information
- Founded
- USCB 2002
- ESPR 2008
- Country
- USCB United States
- ESPR United States
- Employees
- USCB N/A
- ESPR N/A
- Industry
- USCB Major Banks
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- USCB Finance
- ESPR Health Care
- Exchange
- USCB Nasdaq
- ESPR Nasdaq
- Market Cap
- USCB 353.0M
- ESPR 410.2M
- IPO Year
- USCB 2021
- ESPR 2013
- Fundamental
- Price
- USCB $18.20
- ESPR $2.21
- Analyst Decision
- USCB Buy
- ESPR Buy
- Analyst Count
- USCB 4
- ESPR 5
- Target Price
- USCB $16.13
- ESPR $5.13
- AVG Volume (30 Days)
- USCB 26.6K
- ESPR 4.6M
- Earning Date
- USCB 01-23-2025
- ESPR 02-25-2025
- Dividend Yield
- USCB 1.10%
- ESPR N/A
- EPS Growth
- USCB 13.14
- ESPR N/A
- EPS
- USCB 1.04
- ESPR N/A
- Revenue
- USCB $71,791,000.00
- ESPR $295,451,000.00
- Revenue This Year
- USCB N/A
- ESPR $186.88
- Revenue Next Year
- USCB $15.26
- ESPR $22.46
- P/E Ratio
- USCB $17.49
- ESPR N/A
- Revenue Growth
- USCB 10.04
- ESPR 187.12
- 52 Week Low
- USCB $10.25
- ESPR $1.58
- 52 Week High
- USCB $21.86
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- USCB 53.16
- ESPR 44.94
- Support Level
- USCB $16.01
- ESPR $2.05
- Resistance Level
- USCB $18.42
- ESPR $2.40
- Average True Range (ATR)
- USCB 0.64
- ESPR 0.14
- MACD
- USCB 0.11
- ESPR 0.01
- Stochastic Oscillator
- USCB 81.41
- ESPR 45.71
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.